Abstract
Objective: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial found that dual-chamber pacing (DDDR-70) at rates of 70 beats/min or faster in patients with standard indications for an implantable defibrillator but no indication for pacing increased the risk of death or hospitalization for congestive heart failure (CHF). It was not possible to determine from the DAVID trial whether this harm resulted from a faster heart rate from pacing or specifically from the location in the heart where pacing was conducted.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
